BRAF and neoplasm: To assess the effectiveness of SJF-0628 in a broader set of cancer cells representative of diverse biochemical and genetic backgrounds, BRAF genotype, and tumor types, we selected several BRAF V600E-containing CRC and TNBC cell lines (Table 1).